The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Despite the strong military presence, the authorities discovered seven bodies inside a Ford Lobo on 8 October 2011 in Veracruz. On 22 December 2011, three public buses were attacked by drug cartel members on Federal Highway 105 in Veracruz, leaving 16 dead. Three U.S. citizens were among those dead. Soon after the shootouts, which happened in the early morning, the authorities carried out an operation to find those responsible, killing five gunmen. The U.S. Consulate in Matamoros asked Americans to avoid traveling on highways between cities in the late hours of the night. In Tampico Alto, Veracruz, on 23 December 2011 the Mexican authorities found 10 dead bodies after an anonymous call from a citizen. The corpses were dumped on a dirt road, and all of them were handcuffed and presented signs of torture. Nine out of the ten bodies were decapitated. Earlier in February 2011, Saturnino Valdés Llanos, the mayor of the municipality of Tampico Alto, was kidnapped in February 2011; his body was left in a garbage dump with 10 more bodies a week later. On 25 December 2011 near Tampico, Tamaulipas, a city on the border with Veracruz, 13 bodies were found inside an 18-wheeler truck. According to officials, the truck had license plates from Veracruz. Authorities indicated that this massacre was related to the other mass murders that had occurred in Veracruz. On 9 February 2012, the Mexican authorities exhumed 15 bodies from clandestine mass graves in Acayucan, Veracruz.
== Research and development == Generate's research is centered on leveraging machine learning to program proteins for specific functions. Its platform is trained on extensive datasets comprising 160,000 protein structures and 190 million genetic sequences. This system identifies patterns linking protein sequence, structure, and function, which are then used to design new therapeutic proteins. The company's technology includes two core components: de novo protein generation, which allows for the creation of proteins without relying on existing biological templates, and an optimization suite to refine these proteins for therapeutic use. This approach addresses challenges like affinity, immunogenicity, and manufacturability. Generate has applied its platform across various modalities, including antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs). Notable research outputs include antibodies targeting SARS-CoV-2 and preclinical assets in oncology, developed in collaboration with institutions like MD Anderson Cancer Center. To support its experimental work, Generate has invested in advanced facilities, such as a cryogenic electron microscopy (cryoEM) laboratory in Andover, Massachusetts. This lab enables the collection of high-resolution protein interaction data to further train its computational models. Generate's pipeline includes clinical and preclinical candidates addressing conditions like severe asthma and non-small cell lung cancer.
These "de facto experiments investigating the physiology of stress as well as the substances that might alleviate exhaustion" were not unknown outside cycling. Thomas Hicks, an American born in England on 7 January 1875, won the Olympic marathon in 1904. He crossed the line behind a fellow American Fred Lorz, who had been transported for 11 miles of the course by his trainer, leading to his disqualification. However, Hicks's trainer Charles Lucas, pulled out a syringe and came to his aid as his runner began to struggle.
Sources: en.wikipedia.org
== Limitations == One of the main limitations of ITC is that it is prone to allowing only moderate binding conformations to be detected, making it less effective for detecting very weak or extremely tight binding events. Hence, it may struggle to provide accurate thermodynamic parameters for slow kinetic processes with long time constants, as these interactions may be masked by baseline noise and variability. On the other hand, high-affinity interactions can be challenging to measure if they take several minutes or longer to fully develop, or if the measured signal depends on the reaction enthalpy. When the binding enthalpy is close to zero, ITC may fail to generate meaningful interaction data, instead producing a series of small, uniform peaks that result in flat and uninformative thermograms. ITC is also susceptible to interference from unrelated heat signals, making it difficult to isolate and interpret the heat changes associated with the interaction of interest. Other limitations include solubility constraints, challenges in accurately determining protein concentration and the need to prepare the ligand in the same solution conditions as the protein for reliable measurements.
Starbucks Corporation is an American multinational chain of coffeehouses and roastery reserves headquartered in Seattle, Washington. It was founded in 1971 by Jerry Baldwin, Zev Siegl, and Gordon Bowker at Seattle's Pike Place Market initially as a coffee bean wholesaler. Starbucks was converted into a coffee shop serving espresso-based drinks under the ownership of Howard Schultz, who was chief executive officer from 1986 to 2000 and led the aggressive expansion of the franchise across the West Coast of the United States. As of November 2022, the company had 35,711 stores in 80 countries, 15,873 of which were located in the United States. Of Starbucks' U.S.-based stores, over 8,900 are company-operated, while the remainder are licensed. It is the world's largest coffeehouse chain. The company is ranked 120th on the Fortune 500 and 303rd on the Forbes Global 2000, as of 2022. The rise of the second wave of coffee culture is generally attributed to Starbucks, which introduced a wider variety of coffee experiences. Starbucks serves hot and cold drinks, whole-bean coffee, micro-ground instant coffee, espresso, caffe latte, full and loose-leaf teas, juices, Frappuccino beverages, pastries, and snacks. Some offerings are seasonal or specific to the locality of the store. Depending on the country, most locations provide free Wi-Fi Internet access. The company has been subject to multiple controversies related to its business practices. Conversely, its franchise has commanded substantial brand loyalty, market share, and company value.
=== Sports management === Little has been prominently involved in Australian professional sport. Initially in motor racing, Little sponsored John Sidney Racing and Anthony Tratt's Porsche racing team. In 1998 Tratt's team moved into V8 Supercars under Little's ownership as Paul Little Racing. The team folded in 2005 after eight seasons of racing. Little also personally raced competitively but was discouraged by his fellow board members at Toll Holdings due to the danger. On 29 July 2013, Little became the chairman of the Essendon Football Club in the AFL, replacing David Evans. He served in the role for almost two and a half years, presiding over a turbulent time in the club's history as it faced allegations of running a program of illegal supplements during David Evans' tenure. Little stepped down on 14 December 2015, shortly before the final guilty verdict was returned in the supplements investigation, and was replaced by Lindsay Tanner.
Penicillins, like other β-lactam antibiotics, block not only the division of bacteria, including cyanobacteria, but also the division of cyanelles, the photosynthetic organelles of the glaucophytes, and the division of chloroplasts of bryophytes. In contrast, they have no effect on the plastids of the highly developed vascular plants. This supports the endosymbiotic theory of the evolution of plastid division in land plants. Some bacteria produce enzymes that break down the β-lactam ring, called β-lactamases, which make the bacteria resistant to penicillin. Therefore, some penicillins are modified or given with other drugs for use against antibiotic-resistant bacteria or in immunocompromised patients. The use of clavulanic acid or tazobactam, β-lactamase inhibitors, alongside penicillin gives penicillin activity against β-lactamase-producing bacteria. β-Lactamase inhibitors irreversibly bind to β-lactamase preventing it from breaking down the beta-lactam rings on the antibiotic molecule. Alternatively, flucloxacillin is a modified penicillin that has activity against β-lactamase-producing bacteria due to an acyl side chain that protects the beta-lactam ring from β-lactamase.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.